American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

  • Contact Your North Carolina State Senator in Support of H. 206

    The Cancer Treatment Fairness Act (H.206) would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications. It is important you reach out to ask for your North Carolina state Senator's support.

  • President’s Proposed FY 2018 Budget Seeks Massive Cuts to NIH

    President Trump’s fiscal year (FY) 2018 budget outline seeks massive cuts to federal nondefense discretionary (NDD) programs including the National Institutes of Health (NIH). Your elected officials need to hear from you about the importance of sustained and predictable NIH funding.

  • Urge your Representative to Support the Cancer Drug Parity Act

    Legislation has been introduced in the U.S. House of Representatives that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. Your Senators and Representative need to cosponsor these bills in order for them to be considered by the full Congress.

  • Introduce Yourself and Hematology to the New Congress

    The 115th Congress, which includes more than 50 new Representatives and 7 new Senators, has been sworn-in and has already begun conducting legislative business. These newly elected officials – along with returning Senators and Representatives – need to know who you are and what you do, and what they can do to help.

View all action alerts
  • ACA Update

    The House of Representatives released legislation, titled the “American Health Care Act,” to repeal the Affordable Care Act.  As written, ASH has serious concerns that this legislation will reduce overall access to coverage and treatment and would greatly impact patients with hematologic diseases and disorders.

  • DEA Eliminates Grace Period for Registration Renewal

    Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations. 

  • CMS Announces End to Medicare Part B Drug Payment Model

    On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model.  CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.

  • NHLBI Small Business Innovation Research Funding Opportunity Fosters Production of Blood Cells From Stem Cells

    ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.

View all policy news
back to top